Solara Active Pharma Sciences Stock Screener | Share Price & Fundamental Analysis

SOLARA Pharmaceuticals
Screen Solara Active Pharma Sciences share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹576.45
▼ -5.60 (-0.96%)
2026-01-05 00:00:00
Share Price BSE
₹576.25
▼ -6.55 (-1.12%)
2026-01-05 00:00:00
Market Cap ₹1,992.64 Cr.
P/B Ratio 1.61
EPS (TTM) ₹0.14
Dividend Yield -
Debt to Equity 0.89
52W High ₹702.55
52W Low ₹450.30
Operating Margin 17.00%
Profit Margin -0.72%
Revenue (TTM) ₹279.00
EBITDA ₹51.00
Net Income ₹-2.00
Total Assets ₹2,232.00
Total Equity ₹1,097.00

Solara Active Pharma Sciences Share Price History - Stock Screener Chart

Screen SOLARA historical share price movements with interactive charts. Analyze price trends and patterns.

Solara Active Pharma Sciences Company Profile - Fundamental Screener

Screen Solara Active Pharma Sciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SOLARA shares.
Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E
ISIN INE624Z01016

Solara Active Pharma Sciences Balance Sheet Screener - Fundamental Analysis

Fair Value Analysis
Screen SOLARA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
Item 2025 2024 2023 2022 2021 2020 2019 2018
Assets
Total Assets 2,232 2,351 2,899 2,945 2,614 2,154 1,960 1,822
Current Assets 729 801 1,188 1,239 1,058 672 648 608
Fixed Assets 1,193 1,268 1,364 1,356 1,382 1,397 1,218 1,086
Liabilities
Total Liabilities 2,232 2,351 2,899 2,945 2,614 2,154 1,960 1,822
Current Liabilities 191 172 296 354 232 333 344 315
Non-Current Liabilities 0 0 0 0 0 0 0 0
Shareholders' Equity
Total Equity 1,097 937 1,502 1,527 1,593 1,090 960 769
Share Capital 40 36 36 36 36 27 26 25
Reserves & Surplus 1,054 898 1,464 1,489 1,553 963 826 739
Screen SOLARA income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
Item 2025-Mar 2025-Jun 2025-Sept 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec 2022-Mar 2022-Jun 2022-Sept 2022-Dec
Revenue 279 320 314 301 364 347 302 385 354 426 212 367 337 342 402
Expenses 228 262 279 412 322 286 243 332 333 393 436 349 318 311 350
EBITDA 51 58 35 -111 43 62 59 53 21 34 -224 18 20 31 52
Operating Profit % 17.00% 18.00% 11.00% -38.00% 12.00% 18.00% 19.00% 13.00% 5.00% 8.00% -106.00% 3.00% 4.00% 8.00% 11.00%
Depreciation 24 24 25 25 25 25 25 27 26 26 26 28 28 29 28
Interest 29 24 21 31 31 28 27 22 25 24 25 22 23 22 24
Profit Before Tax -2 11 -10 -167 -14 8 8 5 -29 -17 -275 -31 -31 -19 1
Tax 0 0 0 89 0 0 0 1 -10 0 0 -33 -15 -9 0
Net Profit -2 11 -10 -255 -14 8 8 4 -19 -17 -275 2 -17 -10 0
EPS -0.93 2.46 -2.36 -70.93 -3.50 2.54 2.03 1.05 -5.43 -4.77 -72.07 0.53 -4.56 -2.77 0.12

Solara Active Pharma Sciences Cash Flow Screener - Liquidity Fundamentals

Screen SOLARA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
Item 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March
Operating Activities 213 109 156 -242 156 242 166 49
Investing Activities -37 -4 -81 -243 -106 -359 -113 -86
Financing Activities -181 -106 -113 334 93 97 -23 68
Net Cash Flow -5 0 -38 -151 142 -20 30 32
Screen SOLARA shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
Item 2025-Mar 2025-Jun 2025-Sept 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar
Promoter Holding 37.94% 42.01% 42.01% 30.49% 37.27% 37.27% 37.23% 40.97%
FII Holding 14.63% 14.25% 13.58% 15.80% 14.00% 14.25% 14.67% 0.00%
DII Holding 2.61% 2.62% 2.69% 2.97% 2.83% 3.38% 3.19% 2.22%
Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 23.07% 23.47% 24.01% 20.15% 19.61% 18.83% 21.93% 16.23%
Other Holding 21.74% 17.63% 17.70% 30.59% 26.29% 26.28% 22.98% 40.58%
Shareholder Count 75,791 74,334 72,479 73,912 78,617 71,882 83,148 76,325

Solara Active Pharma Sciences Dividend Screener - Share Yield Analysis

Screen SOLARA dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Period Dividend Per Share Dividend Yield
2025-March ₹0.00 0.00%
2024-March ₹0.00 0.00%
2023-March ₹3.00 0.88%
2022-March ₹0.00 0.00%
2021-March ₹7.00 1.14%
2020-March ₹2.00 0.16%
2019-March ₹5.00 1.22%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%
2016-March ₹0.00 0.00%

Solara Active Pharma Sciences Index Membership - Market Screener Classification

Screen SOLARA by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.

Solara Active Pharma Sciences Market Events Screener - Corporate Actions

Screen SOLARA market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
Announcement Date Record Date Event Type Information Price Impact
Annual General Meeting NA 1.99%
Annual General Meeting NA 6.04%
2025-11-05 2025-11-05 Quarterly Result Announcement NA 4.97%
2025-07-25 2025-07-25 Quarterly Result Announcement NA -5.15%
2025-05-15 2025-05-15 Quarterly Result Announcement NA 19.48%
2025-01-24 2025-01-24 Quarterly Result Announcement NA 4.29%
2024-10-21 2024-10-21 Quarterly Result Announcement NA 8.18%
2024-05-15 2024-05-15 Rights 1:3 8.26%
2021-08-18 2021-08-20 Dividend ₹ 3.00 /share 5.36%
2017-03-25 2017-03-25 Change Of Name NA -

Solara Active Pharma Sciences Competitors Screener - Peer Comparison

Screen SOLARA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 412,734 39.30 54,729 9.71% 10,980 39.06
Divis Laboratories 168,851 68.25 9,712 18.67% 2,191 44.96
Torrent Pharmaceuticals 129,357 59.98 11,539 6.99% 1,911 59.35
Cipla 120,557 22.21 28,410 7.12% 5,291 42.76
Dr Reddys Laboratories 105,645 18.46 33,741 16.73% 5,725 49.97
Lupin 95,023 21.85 22,910 13.74% 3,306 50.10
Zydus Life Science 90,707 18.09 23,511 18.55% 4,615 34.06
Mankind Pharma 88,846 50.78 12,744 20.90% 2,007 40.67
Aurobindo Pharma 68,901 20.36 32,346 9.43% 3,484 46.33
Alkem Laboratories 65,390 27.28 13,458 3.70% 2,216 37.45

Solara Active Pharma Sciences Company Announcements - News Screener

Screen SOLARA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
Date Update Actions
2025-12-31 Closure of Trading Window View
2025-12-17 Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS View
2025-12-17 Reconstitution Of The Management Committee View
2025-12-17 Announcement under Regulation 30 (LODR)-Change in Directorate View
2025-12-17 Board Meeting Outcome for Board Meeting Outcome For Solara Active Pharma Sciences Limited Held On December 17 2025 View
2025-12-05 Announcement under Regulation 30 (LODR)-Resignation of Director View
2025-12-04 Clarification On Volume Movement View
2025-12-04 Clarification sought from Solara Active Pharma Sciences Ltd -
2025-11-19 Announcement under Regulation 30 (LODR)-Press Release / Media Release View
2025-11-11 Announcement under Regulation 30 (LODR)-Earnings Call Transcript View
2025-11-06 Announcement under Regulation 30 (LODR)-Newspaper Publication View
2025-11-06 Announcement under Regulation 30 (LODR)-Monitoring Agency Report View
2025-11-05 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome View
2025-11-05 General-Updates View
2025-11-05 Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS View
2025-11-05 Statement Of Deviation And Variation For Funds Raised Under Rights Issue For The Quarter Ended September 30 2025. View
2025-11-05 Intimation Regarding The Grant Of ESOP View
2025-11-05 Intimation About Appointment Of Mr. Mohanraj S As Chief Human Resources Officer (CHRO) View
2025-11-05 Announcement under Regulation 30 (LODR)-Press Release / Media Release View
2025-11-05 Announcement under Regulation 30 (LODR)-Resignation of Director View